Modafinil to Reduce Persistent Fatigue in Patients Following Treatment for Cancer
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of modafinil with regard to reducing
cancer-related fatigue in cancer patients following chemotherapy or radiation therapy.
Secondarily, the effect of modafinil on cognitive dysfunction in the same population will be
assessed.
The researchers hypothesize that administering modafinil (PROVIGIL®) to patients experiencing
fatigue following completion of cancer treatment will lead to reduction in patient fatigue
and prevention of or improvement in patient cognitive dysfunction.